Development and validation of a PD-L1 and tumor mutational burden-based predictive model for pathological complete response after neoadjuvant immunotherapy in resectable lung cancer

International Journal of Clinical Pharmacy · Published 2026-07-29 · DOI 10.1007/s11096-026-02191-3

Free full text

Authors (3)

Xiao Wu, Duo Jiang, Bin Li

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wu, X., Jiang, D., Li, B. (2026). Development and validation of a PD-L1 and tumor mutational burden-based predictive model for pathological complete response after neoadjuvant immunotherapy in resectable lung cancer. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-026-02191-3

Related articles

• Perspectives on shared decision making related to medications from patients with multiple long-term conditions transitioning from hospital to home: a qualitative study · International Journal of Clinical Pharmacy · 2026 · Same journal
• Development of a real-world, therapeutic drug monitoring–informed model to predict teicoplanin daily dose in pediatric intensive care unit patients with bacterial infections · International Journal of Clinical Pharmacy · 2026 · Same journal
• Comment on “evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation” · International Journal of Clinical Pharmacy · 2026 · Same journal
• Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System · International Journal of Clinical Pharmacy · 2026 · Same journal
• Patient perspectives on atrial fibrillation management and pharmacist roles in outpatient clinics: a qualitative study · International Journal of Clinical Pharmacy · 2026 · Same journal
• Active surveillance and risk prediction of piperacillin/tazobactam‑associated hypokalaemia: development and external validation of a clinical nomogram · International Journal of Clinical Pharmacy · 2026 · Same journal
• Consumers’ experiences and perspectives on reporting adverse drug reactions using digital tools: a qualitative study · International Journal of Clinical Pharmacy · 2026 · Same journal
• Grounding clinical supervision in advanced pharmacy practice: a new conceptual model · International Journal of Clinical Pharmacy · 2026 · Same journal
• A multi-method study of unlicensed medicine risk assessment: a cross-sectional survey of pharmacy procurement leads and policy analysis across NHS trusts in England · International Journal of Clinical Pharmacy · 2026 · Same journal
• A qualitative exploration of healthcare professionals’ perspectives on the role of pharmacists in screening older adults for depression during medication reviews · International Journal of Clinical Pharmacy · 2026 · Same journal